New & Noteworthy

June 2021

Multiplex Test Within COVID-19 Portfolio

QIAGEN

The NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test from QIAGEN is a 4-plex test that utilizes the high-throughput, automated testing capabilities of the NeuMoDx systems, with a growing assay menu for respiratory, blood-borne virus, transplant, and reproductive health disease areas. Having received Emergency Use Authorization by the US FDA, the assay aims to help health professionals quickly identify and differentiate individuals suspected of respiratory viral infection consistent with COVID-19. This polymerase chain reaction (PCR) multiplex test is a tool designed to assist with simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV), and SARS-CoV-2 infections within 80 minutes. The new test joins a growing menu of assays on the NeuMoDx platform, which includes tests for blood-borne viruses, sexual and reproductive health, and transplant and immunocompromised disease areas.

  • QIAGEN
Request More Information

Current Issue